General Updates

September 23, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited, strengthening Jagsonpal’s presence in Women’s Health Dear Sir/ Madam, Pursuant to Regulation 30 read with Para A(1) of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”), we wish to inform you that Jagsonpal Pharmaceuticals Limited (“Company”) has entered into a Business Transfer Agreement (“BTA”) with Group Pharmaceuticals Limited (“Seller”) on September 23, 2026, for acquisition of the Wellness Portfolio of the Seller, on a going-concern basis by way of slump sale, subject to the terms and conditions contained in the BTA. The acquisition of the portfolio is in line with the Company's strategic objective of strengthening and expanding its pharmaceutical portfolio, enhancing its presence in the relevant therapeutic segments and expanding its market reach. The detailed disclosure as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/l/3762/2026 updated as on January 30, 2026 are enclosed herewith as Annexure-A. A press release being issued by the Company in this regard is attached as Annexure -B. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance office Annexure-A Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Sr. Particulars Information a) Name of the target entity, details in brief Not applicable. Company proposes to acquire the such as size, turnover etc. Wellness Portfolio of Group Pharmaceuticals Limited. Turnover of the portfolio for FY 2025-26 was ₹24.6 Crores. b) Whether the acquisition would fall within The said business transfer does not fall within the related party transaction(s) and whether purview of related party transactions. None of the the promoter/ promoter group/ group promoter/promoter group/group companies have any companies have any interest in the entity interest in the Wellness Portfolio / Seller. being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” c) Industry to which the entity being acquired Pharmaceutical Industry belongs d) Objects and effects of acquisition The acquisition will strengthen the Company’s (including but not limited to, disclosure of pharmaceutical portfolio, expand its presence across reasons for acquisition of target entity, if relevant therapeutic segments and enhance market its business is outside the main line of reach. business of the listed entity) e) Brief details of any governmental or None regulatory approvals required for the acquisition f) Indicative time period for completion of On or before 01 November, 2026, subject to fulfilment of the acquisition conditions precedent and other terms of the BTA. g) Nature of consideration - whether cash Initial consideration of ₹23.7 crores on closing. Additional consideration or share swap and details of consideration linked to FY 2027-28 sales of upto ₹23.0 the same Crores, subject to a total consideration cap of ₹46.7 Crores. h) Cost of acquisition or the price at which Not applicable the shares are acquired i) Percentage of shareholding/ control Not applicable acquired and/ or number of shares acquired j) Brief background about the entity Not applicable. The Company proposes to acquire the acquired in terms of products/line of Wellness Portfolio of Group Pharmaceuticals Limited, business acquired, date of incorporation, which is engaged in the pharmaceutical business, on a history of last 3 years turnover, country in going-concern basis by way of slump sale. The business which the acquired entity has presence has presence in India and comprises the identified and any other significant information (in products, assets, contracts, employees and other brief) arrangements relating to the business. Annexure-B Jagsonpal Pharmaceuticals to acquire Wellness Portfolio of Group Pharmaceuticals. Acquisition to strengthen product portfolio and existing market presence Gurugram, India | September 23, 2026 – Jagsonpal Pharmaceuticals Ltd. (Jagsonpal) today announced the execution of a Business Transfer Agreement (“BTA”) with Group Pharmaceuticals Limited (“Group Pharma”) for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The transaction involves Initial consideration of ₹23.7 crores on closing. Additional consideration linked to FY 2027-28 sales of upto ₹23.0 Crores, subject to a total consideration cap of ₹46.7 Crores. The transaction is expected to be completed on or before 01 November, 2026, subject to fulfilment of the conditions precedent and other terms and conditions stipulated under the BTA. This business brings in an established portfolio of products and an existing market presence, which we intend to integrate with its existing commercial platform and capabilities while leveraging its existing distribution network to create operating synergies. Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: " The acquisition marks another meaningful step in our growth journey. It strengthens our pharmaceutical portfolio and expands our presence across complementary therapeutic segments especially in women healthcare, while remaining consistent with our asset-light and focused approach to growth. We remain focused on pursuing opportunities that complement our existing capabilities and create sustainable, long-term value for all our stakeholders.” Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: “We are delighted to welcome this portfolio and the employees of the business into our organization, and are fully committed to ensuring their smooth and seamless integration. We are equally excited about this acquisition as we embark on our next phase of growth, expanding our field force, strengthening our pan-India presence and creating significant cross-selling opportunities across our portfolio. Together, we look forward to a seamless transition and unlocking the portfolio’s full growth potential by leveraging our established commercial infrastructure and strong execution capabilities.” The transaction is subject to the fulfilment of applicable conditions precedent and other customary closing conditions as set out in the BTA. Think law Advisors represented Jagsonpal as their legal Advisors while Tatva Legal advised Group Pharma on the transaction. ABOUT JAGSONPAL PHARMACEUTICALS LIMITED Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over five decades in the Indian pharmaceutical market. The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, and Dermatology segments. Over the years, the Company has successfully built multiple brands that today hold market- leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 1000 professionals. The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi. For more information, please visit: www.jagsonpal.com Co [Showing first 8,000 characters — download PDF for full document]